Role of IV Infusion of Dexmedetomidine in prevention of PPH.

To compare the effectiveness of Dexmedetomidine combined with Standard treatment versus Standard treatment in the prevention of PPH : A prospective,randomized controlled trial. - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105307

Enrollment

Registered

2026-03-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: -

Interventions

Intervention1: DEXMEDETOMIDINE IV INFUSION STANDARD TREATMENT: Dexmedetomidine dose of 0.5mcg/kg/hriv infusionbefore giving SA/GA till the proper recovery of uterine tone . and Oxytocin 10IU iv /im f

Eligibility

Inclusion criteria

Inclusion criteria: Age 18 45 years Pregnant female scheduled for c-section under Spinal anaesthesia or General anaesthesia High risk for PPH (e.g uterine atony, multiple gestation, polyhydramnios, macrosomia, prior PPH, Pre- eclampsia and prolonged labor) Hemodynamically stable ASA (American Society of Anesthesiologist) physical status (1-4)

Exclusion criteria

Exclusion criteria: Hemodynamically unstable: Hypotension, Hypovolemia Pre-existing use of alpha-2 agonists Hyposensitivity to Dexmedetomidine 2nd or 3rd degree heart block. Sick sinus syndrome Fetal heart block

Design outcomes

Primary

Measure	Time frame
Prevention of Postpartum hemorrhageTimepoint: After starting Dexmedetomidine infusion Before delivery of Baby After delivery of Baby	—

Secondary

Measure	Time frame
To evaluate hemodynamic stability. To compare the need for blood transfusion between groups. To assess maternal morbidity (organ dysfunction, ICU stay, need for surgical intervention). To assess the incidence of ICU admission and duration of hospital stay. To evaluate sedation and pain scores. To evaluate effect of dexmedetomidine on fetus (APGAR score), before surgery FHR and post-surgery FHR. To document any adverse effects attributable to dexmedetomidineTimepoint: After starting Dexmedetomidine infusion Before delivery of Baby After delivery of Baby , 24 hr post delivery.	—

Measure

Time frame

To evaluate hemodynamic stability. To compare the need for blood transfusion between groups. To assess maternal morbidity (organ dysfunction, ICU stay, need for surgical intervention). To assess the incidence of ICU admission and duration of hospital stay. To evaluate sedation and pain scores. To evaluate effect of dexmedetomidine on fetus (APGAR score), before surgery FHR and post-surgery FHR. To document any adverse effects attributable to dexmedetomidineTimepoint: After starting Dexmedetomidine infusion Before delivery of Baby After delivery of Baby , 24 hr post delivery.

—

Countries

India

Contacts

Public ContactDrAjay Kumar

SGT UNIVERSITY

dattvishnu@yahoo.com9718599406

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026